Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Blood|October 5, 2011
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaNobuko Hijiya, Blythe Thomson, Michael S Isakoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology GroupKatherine A Janeway, Alexander J Chou, Allen Buxton, et al.
International Journal of Cancer|May 29, 2023
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastomaDon Eslin, Peter E Zage, Genevieve Bergendahl, et al.
Cancer|August 25, 2024
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor BoardAjay Gupta, Matthew S Dietz, Richard F Riedel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma TrialsDamon R Reed, Asmin Tulpule, Jonathan Metts, et al.
Blood Advances|December 3, 2025
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH studyAdi Zoref-Lorenz, Carl E Allen, Edward M Behrens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2024
Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer FoundationAditi Dhir, Masanori Hayashi, Avery Bodlak, et al.
Pediatric Blood & Cancer|October 15, 2013
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancerNathan J Robison, Federico Campigotto, Susan N Chi, et al.
Cancer Reports (Hoboken, N.J.)|March 31, 2022
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastomaJacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, et al.
Genome Medicine|February 12, 2024
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trialGiselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, et al.
Pageof 4